Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2006JAMA

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTim BongartzVanderbilt University Medical CenterASAlex J. SuttonLuminex (United States)MSMichael SweetingVascular Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bongartz et al. (2006) studied this question.

synapsesocial.com/papers/69f2641f2574b3da7eabc3c8https://doi.org/10.1001/jama.295.19.2275
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improving the Quality of Reports of Meta-Analyses of Randomised Controlled Trials: The QUOROM Statement2000 · 238 citations
  2. 2Quantifying heterogeneity in a meta‐analysis2002 · 37,607 citations
  3. 3Human lymphotoxin has at least equal antitumor activity in comparison to human tumor necrosis factor but is less toxic in mice1995 · 26 citations
  4. 4Infections in patients with rheumatoid arthritis treated with biologic agents2005 · 689 citations
  5. 5Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report2005 · 256 citations